February 7th 2025
New technology is creating new opportunities but is also causing new complications.
The UK's Post-Brexit Life Sciences Strategy: Outlook and Implications
September 5th 2017Following the unveiling of the UK’s post-Brexit life sciences strategy, Neil Grubert looks at the measures related to market access, a particular challenge in the UK market and key to its future success in the sector.
5 Ways to Ensure Early Engagement with Payers and Regulators Pays Off
September 4th 2017As regulators lower evidentiary requirements for approval to speed development and review of new drugs for unmet medical needs, payers are demanding more data to justify price premiums. Companies need to be strategic in how they navigate these complexities, write Bengt Anell, Sangeeta Budhia and Richard Macaulay.
Pharma and Biotech Markets: Mostly Sunny, But An Uncertain Forecast
May 9th 2017Pharm Exec's Editorial Advisory Board member, Peter Young, cover a summary of the strategic issues facing the biopharma industry, but goes on to tell the story of what happened last year and this first quarter in terms of the stock market, M&A and financing (including IPOs) activity, where it is headed, and the implications for senior management.
Region in Reform? Access Pains and Gains in Latin America
February 28th 2017Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry